Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.

Abstract

The aim of the present study was to examine modifications of anti-tumor activity and toxicity of paclitaxel (PLX) when given p.o. after recombinant interleukin-2 (rIL-2) to Lewis lung carcinoma-bearing mice. PLX was given orally to mice at the dose of 15 mg/kg on day 8 and 30 mg/kg on day 15, either alone or after 16.5 microg of rIL-2 given i.p. twice a day either 1 or 3 days before. The anti-tumor activity was higher and PLX hematological toxicity not increased if orally administered PLX was given after a 3-day rIL-2 pre-treatment rather than if given alone. Lung metastasis was significantly lower and s.c. tumors were smaller in the PLX+rIL-2 group than in the PLX or rIL-2 or non-treated groups. In addition, a decrease in lung P-glycoprotein expression (investigated by Western blot analysis) was observed 1 h after the last administration of rIL-2 on day 7.

• Authors: Benoît Hosten, Désiré Challuau, Sophie Gil, Céline Bouquet, Sylvie Marion, Michel Perricaudet, Mario Di Palma, Robert Farinotti, Laurence Bonhomme-Faivre
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 17 Issue 2 Pg. 195-9 (Feb 2006) ISSN: 0959-4973 [Print] England
• PMID: 16428938 (Publication Type: Journal Article)

Chemical References

• ATP Binding Cassette Transporter, Subfamily B, Member 1
• Antineoplastic Agents, Phytogenic
• Interleukin-2
• Recombinant Proteins
• Paclitaxel

Topics

• ATP Binding Cassette Transporter, Subfamily B, Member 1 (metabolism)
• Administration, Oral
• Animals
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Blotting, Western
• Carcinoma, Lewis Lung (drug therapy, metabolism)
• Combined Modality Therapy
• Female
• Injections, Subcutaneous
• Interleukin-2 (therapeutic use)
• Lung (drug effects, metabolism)
• Mice
• Mice, Inbred C57BL
• Paclitaxel (administration & dosage)
• Recombinant Proteins (therapeutic use)